A share price of Achilles Therapeutics Plc ADR [ACHL] is currently trading at $1.38, down -0.72%. An important factor to consider is whether the stock is rising or falling in short-term value. The ACHL shares have gain 22.12% over the last week, with a monthly amount glided 15.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Achilles Therapeutics Plc ADR [NASDAQ: ACHL] stock has seen the most recent analyst activity on April 05, 2024, when Piper Sandler downgraded its rating to a Neutral and also revised its price target to $2 from $8. Previously, Piper Sandler started tracking the stock with Overweight rating on April 26, 2021, and set its price target to $25. On April 26, 2021, Oppenheimer initiated with a Outperform rating and assigned a price target of $23 on the stock. JP Morgan started tracking the stock assigning a Underweight rating and suggested a price target of $11 on April 26, 2021. Chardan Capital Markets initiated its recommendation with a Buy and recommended $27 as its price target on April 26, 2021. BofA Securities started tracking with a Buy rating for this stock on April 26, 2021, and assigned it a price target of $20.
Achilles Therapeutics Plc ADR experienced fluctuations in its stock price throughout the past year between $0.63 and $1.76. Currently, Wall Street analysts expect the stock to reach $2 within the next 12 months. Achilles Therapeutics Plc ADR [NASDAQ: ACHL] shares were valued at $1.38 at the most recent close of the market. An investor can expect a potential return of 44.93% based on the average ACHL price forecast.
Analyzing the ACHL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.55, Equity is -0.55 and Total Capital is -0.69. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3733 points at the first support level, and at 1.3667 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3883, and for the 2nd resistance point, it is at 1.3967.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Achilles Therapeutics Plc ADR [NASDAQ:ACHL] is 6.04. On the other hand, the Quick Ratio is 6.04, and the Cash Ratio is 4.66.
Transactions by insiders
Recent insider trading involved Moses Edwin, Director, that happened on Feb 06 ’25 when 25000.0 shares were purchased. Former Director, Giordano Michael F completed a deal on Feb 04 ’25 to buy 25000.0 shares. Meanwhile, Director BOESS CARSTEN bought 25000.0 shares on Feb 04 ’25.
